Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo de revisión (ReviewArticle)

Evaluation of the recombinant protein -TSP-2 for the serological diagnosis of imported urogenital schistosomiasis and comparison with commercially available tests

  • Luzón-García, María Pilar
  • Navarro, Laura
  • Rodríguez, Esther
  • Soriano-Pérez, Manuel Jesús
  • Vázquez-Villegas, José
  • Cabeza-Barrera, María Isabel
  • Loukas, Alex
  • Castillo-Fernández, Nerea
  • Perteguer-Prieto, Maria Jesus
  • Sotillo, Javier
  • Salas-Coronas, Joaquin
Different agencies have emphasized the need to evaluate current serological methods for screening patients with suspected urogenital schistosomiasis. However, there is still a lack of evidence regarding the most appropriate methods for this purpose. Here we assessed the diagnostic efficacy of a newly developed serological technique that utilizes the recombinant protein -TSP-2, applied to the urine and serum of migrants suspected of having urogenital schistosomiasis. The sensitivity, specificity, positive and negative predictive values of an in-house enzyme-linked immunosorbent assay (ELISA) using the recombinant protein -TSP-2 were analysed and compared with other commercial serological methods. Due to the limitations of microscopy as a perfect reference method, a latent class analysis (LCA) and composite reference standard (CRS) approach was used to determine the sensitivity and specificity of each test. According to the LCA model, the commercial tests NovaLisa and immunochromatography test (ICT) immunoglobulin G–immunoglobulin M (IgG–IgM) presented the highest sensitivity (100%), whereas the -TSP-2 serum ELISA test had 79.2%. The -TSP-2 urine and serum ELISA tests had the highest specificities among the serological methods (87.5 and 75%, respectively). CRS modelling showed that the ICT IgG–IgM, NovaLisa and -TSP-2 serum tests led in sensitivity at 97.1, 88.6 and 71.4%, respectively, with all tests except that the ICT IgG–IgM test having a specificity >90%. -TSP-2 has been validated as a screening tool for patients suspected of having urogenital schistosomiasis. Although commercial serological tests have shown higher sensitivities, -TSP-2 could be valuable for confirming results from tests with lower specificity. Nevertheless, further studies with larger patient cohorts are necessary to fully verify its potential.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A genetic profiling guideline to support diagnosis and clinical management of lymphomas

  • Sánchez-Beato, Margarita
  • Méndez, Miriam
  • Guirado-Risueño, María
  • Pedrosa, Lucía
  • Sequero, Silvia
  • Yanguas-Casás, Natalia
  • Cruz-Merino, Luis de la
  • Prieto, Laura
  • Llanos, Marta
  • García, Juan Fernando
  • Provencio, Mariano
The new lymphoma classifications (International Consensus Classification of Mature Lymphoid Neoplasms, and 5th World Health Organization Classification of Lymphoid Neoplasms) include genetics as an integral part of lymphoma diagnosis, allowing better lymphoma subclassification, patient risk stratification, and prediction of treatment response. Lymphomas are characterized by very few recurrent and disease-specific mutations, and most entities have a heterogenous genetic landscape with a long tail of recurrently mutated genes. Most of these occur at low frequencies, reflecting the clinical heterogeneity of lymphomas. Multiple studies have identified genetic markers that improve diagnostics and prognostication, and next-generation sequencing is becoming an essential tool in the clinical laboratory. This review provides a "next-generation sequencing" guide for lymphomas. It discusses the genetic alterations of the most frequent mature lymphoma entities with diagnostic, prognostic, and predictive potential and proposes targeted sequencing panels to detect mutations and copy-number alterations for B- and NK/T-cell lymphomas., The work of the Grupo de Investigación en Linfomas-IDIPHISA is supported by the ISCIII-MINECO AES-FEDER (Plan Estatal de I+D+I 2017-2020; PI17/00272, PI20/00691); GILEAD (GL18/00019), Dirección General de Universidades e Investigación Consejería de Educación e Investigación de la Comunidad de Madrid (B2017/BMD-3778) and Fundación de Investigación Biomédica H.U. Puerta de Hierro-Majadahonda. LP is recipient of iPFIS predoctoral fellowships (IFI18/0004), by ISCIII/MINECO AES-FEDER (Plan Estatal I+D+I 2017-2020) and NYC is supported by the Fundación Asociación Española Contra el Cáncer., Peer reviewed